分团注射胰腺CTA方案用于胰腺癌局部分期及肝病灶检出与定性
回顾性纳入82例胰腺癌患者,评估分团注射胰腺CTA对原发肿瘤局部分期及肝病灶检出与定性的价值;肝病灶诊断准确率97.8%(89/91)、敏感度96.7%(58/60)、特异度100%(33/33);主观图像质量在超过89%的病例中为最佳,无不可诊断图像。
要点
- 分团注射胰腺CTA可同时完成胰腺癌原发灶局部分期与肝病灶检出定性。
- 肝病灶诊断准确率97.8%(89/91)、敏感度96.7%(58/60)、特异度100%(33/33)。
- 各结构主观图像质量在超过89%的病例中为最佳,无不可诊断评级。
核心结论
- 分团注射胰腺CTA方案可用于胰腺癌检测与分期,既覆盖原发肿瘤,也支持肝病灶的检出与定性。
研究设计与样本
- 经IRB批准、符合HIPAA的回顾性研究,连续纳入2015年12月至2016年12月间接受分团注射胰腺CTA的胰腺癌患者82例,以复合参考标准验证肝病灶诊断准确性。
关键影像表现/征象
- 胰腺病灶的肿瘤显著度和对比噪声比分别为60.8±35.1 HU和8.0±5.8。
- 肝病灶的肿瘤显著度和对比噪声比分别为58±34.7 HU和9.7±6.3。
诊断标准与关键数值
- 分团注射方案对肝病灶的诊断准确率为89/91(97.8%,95%CI 92.3-99.4)。
- 分团注射方案对肝病灶的诊断敏感度为58/60(96.7%,95%CI 88.6-99.1)。
- 分团注射方案对肝病灶的诊断特异度为33/33(100%,95%CI 89.6-100)。
临床应用与阅片要点
- 由一名20年经验的腹部放射科医生对图像质量进行主观评价,并盲法检出和定性肝病灶。
- 任何不确定的发现或分级评分与另一名7年经验的腹部放射科医生共识评估。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To validate the use of a split-bolus pancreas CTA protocol for local staging of pancreatic cancer and to evaluate its ability to detect and characterize liver lesions.
METHODS: Consecutive patients with pancreatic cancer who underwent split-bolus pancreas CTA between 12/2015 and 12/2016 were included in this IRB-approved HIPAA-compliant retrospective study. Objective evaluation of the abdominal vessels, the pancreas, the liver, and lesions, if present, was performed with attenuation measurements and tumor conspicuity and contrast-to-noise ratio (CNR) calculations. An abdominal radiologist with 20 years of experience performed subjective evaluation of image quality and blindly detected and characterized liver lesions. Any inconclusive findings or grading scores were evaluated in consensus with another abdominal radiologist with 7 years of experience. Liver findings were validated using a composite reference standard to assess accuracy.
RESULTS: There were 82 pancreatic cancer patients with a total of 91 liver findings. Tumor conspicuity and CNR were 60.8 ± 35.1 HU and 8.0 ± 5.8 for the pancreatic lesions and 58 ± 34.7 HU and 9.7 ± 6.3 for the liver lesions, respectively. The accuracy, sensitivity, and specificity of the split-bolus protocol for the hepatic findings were correspondingly 89/91 (97.8%, 95% CI 92.3-99.4), 58/60 (96.7%, 95% CI 88.6-99.1), and 33/33 (100%, 95% CI 89.6-100). The subjective image quality ratings were optimal in more than 89% of the cases for various structures, with no non-diagnostic ratings.
CONCLUSION: Split-bolus pancreas CTA protocol allows for detection and staging of pancreatic cancer, both for the primary tumor and detection and characterization of liver lesions.
引用
- Camacho A, Fang J, Cohen MP, et al. Split-bolus pancreas CTA protocol for local staging of pancreatic cancer and detection and characterization of liver lesions. Abdom Radiol (NY). 2018. PMID: 29063133. doi:10.1007/s00261-017-1350-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。